Immunicum AB (publ) Announces Publication of Abstracts for the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium
February 03, 2020 17:00 ET
|
Immunicum AB
Press Release 3 February 2020 Immunicum AB (publ) Announces Publication of Abstracts for the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium Immunicum AB (publ; IMMU.ST) announced today the...
Taconic Biosciences Launches New Immuno-oncology Mouse Model
January 31, 2020 09:00 ET
|
Taconic Biosciences
RENSSELAER, N.Y., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, expands its premier immuno-oncology portfolio with the...
Immunicums MERECA-studie utvald för muntlig presentation vid ASCO-SITC Clinical Immuno-Oncology Symposium
December 20, 2019 02:55 ET
|
Immunicum AB
Pressmeddelande 20 december 2019 Immunicums MERECA-studie utvald för muntlig presentation vid ASCO-SITC Clinical Immuno-Oncology Symposium Immunicum AB (publ) meddelade i dag att abstraktet med...
Immunicum AB (publ) Announces Upcoming Oral Presentation on MERECA Trial at the ASCO-SITC Clinical Immuno-Oncology Symposium
December 20, 2019 02:55 ET
|
Immunicum AB
Press Release 20 December 2019 Immunicum AB (publ) Announces Upcoming Oral Presentation on MERECA Trial at the ASCO-SITC Clinical Immuno-Oncology Symposium Immunicum AB (publ; IMMU.ST) announced...
Carlos de Sousa avgår som vd för Immunicum AB (publ)
December 13, 2019 02:30 ET
|
Immunicum AB
Pressmeddelande 13 december 2019 Carlos de Sousa avgår som vd för Immunicum AB (publ) Styrelsen i Immunicum har kommit överens med Carlos de Sousa om att han lämnar rollen som verkställande...
Immunicum AB (publ) Announces Resignation of Carlos de Sousa as CEO
December 13, 2019 02:30 ET
|
Immunicum AB
Press Release 13 December 2019 Immunicum AB (publ) Announces Resignation of Carlos de Sousa as CEO The Board of Directors of Immunicum announced today that, by mutual agreement, Carlos de Sousa...
Provectus Announces Presentation of Preliminary Results from Phase 1 Trial of PV-10® (rose bengal disodium) for Treatment of Metastatic Uveal Melanoma at ESMO I-O Congress 2019
December 12, 2019 08:00 ET
|
Provectus Biopharmaceuticals Inc.
13 patients treated to date have received single-agent PV-10 or combination of PV-10 and standard of care checkpoint blockadeIndependent safety profiles of PV-10 and checkpoint inhibition were...
Fluidigm Expands Maxpar Antibody Portfolio for High-Multiplex Tissue Imaging
December 10, 2019 08:30 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), the global leader in high-multiplex single-scan tissue imaging, today announced the availability of...
Innate Pharma présente Lumoxiti®, médicament approuvé par la FDA, au congrès de l'ASH 2019
December 08, 2019 09:00 ET
|
INNATE PHARMA
L'analyse finale s'appuie sur les résultats de l'étude pivot de Phase III de Lumoxiti dans la leucémie à tricholeucocytes ; des réponses complètes et durables sont maintenues dans les données de suivi...
Innate Pharma highlights FDA-approved Lumoxiti® at ASH 2019
December 08, 2019 09:00 ET
|
INNATE PHARMA
Final analysis expands on efficacy results from pivotal Phase III trial of Lumoxiti in hairy cell leukemia; durable, complete responses maintained in long-term follow-up data Innate...